Triple-negative breast cancer (TNBC), which accounts for approximately 10% to 15% of breast cancers, remains the most aggressive subtype and is characterized by early disease relapse for a subset of patients. TNBC remains a clinical challenge, given the lack of effective targeted treatments such as endocrine therapy for hormone receptor-positive (HR+) tumors or therapies against HER2.
|Original language||English (US)|
|Number of pages||7|
|Journal||Oncology (Williston Park, N.Y.)|
|State||Published - May 13 2020|
ASJC Scopus subject areas
- Cancer Research